mCART19

mCART19 is a murine chimeric antigen receptor (CAR) T cell therapy specifically engineered to target the B-lymphocyte antigen CD19. The construct is typically composed of a single-chain variable fragment (scFv) derived from the anti-mouse CD19 antibody clone 1D3, linked to murine-derived signaling components including the CD8 transmembrane region, a CD28 co-stimulatory domain, and a CD3 zeta signaling domain. In preclinical research, particularly at institutions like Washington University School of Medicine, mCART19 is utilized as a benchmark or control treatment in immunocompetent mouse models to evaluate the efficacy and safety of novel CAR T therapies. It functions by inducing the targeted lysis of CD19-positive cells, including normal B cells and malignant cells engineered to express the CD19 antigen.

Other names

murine CD19-targeting CAR T cellsmurine CAR191D3-based CAR T cells